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ABSTRACT
Purpose: The purpose of this research was to identify
factors predicting response to preoperative chemotherapy.
Experimental Design: In a large volume laboratory us-
ing standard immunohistochemical methods, we reviewed
the pretreatment biopsies and histologic specimens at final
surgery of 399 patients with large or locally advanced breast
cancer (cT2-T4, N0–2, M0) who were treated with preoper-
ative chemotherapy. The incidence of pathological complete
remission and the incidence of node-negative status at final
surgery were assessed with respect to initial pathological
and clinical findings. Menopausal status, estrogen receptor
status, progesterone receptor status [absent (0% of the cells
positive) versus expressed], clinical tumor size, histologic
grade, Ki-67, Her-2/neu expression, and type and route of
chemotherapy were considered.
Results: High rates of pathological complete remission
were associated with absence of estrogen receptor and pro-
gesterone receptor expression (P < 0.0001), and grade 3
(P 0.001). Significant predictors of node-negative status at
surgery were absence of estrogen receptor and progesterone
receptor expression (P < 0.0001), clinical tumor size <5 cm
(P < 0.001), and use of infusional regimens (P  0.003). The
chance of obtaining pathological complete remission or
node-negative status for patients with endocrine nonrespon-
sive tumors compared with those having some estrogen
receptor or progesterone receptor expression was 4.22 (95%
confidence interval, 2.20–8.09, 33.3% versus 7.5%) and 3.47
(95% confidence interval, 2.09–5.76, 42.9% versus 21.7%),
respectively. Despite the significantly higher incidence of
pathological complete remission and node-negative status
achieved by preoperative chemotherapy for patients with
estrogen receptor and progesterone receptor absent disease,
the disease-free survival was significantly worse for this
cohort compared with the low/positive expression cohort
(4-year disease-free survival %: 41% versus 74%; hazard
ratio 3.22; 95% confidence interval, 2.28–4.54; P < 0.0001).
Conclusions: Response to preoperative chemotherapy is
significantly higher for patients with endocrine nonrespon-
sive tumors. New chemotherapy regimens or combinations
should be explored in this cohort of patients with poor
outcome. For patients with endocrine responsive disease, the
role of preoperative endocrine therapies should be studied.
INTRODUCTION
Experimental data support the hypothesis that chemother-
apy given before surgery for breast cancer may improve patient
outcome (1–4), yet the most effective timing and sequencing for
systemic chemotherapy in operable breast cancer is still unclear.
Outside clinical trials, such treatment is indicated only for
patients with locally advanced disease or those in whom a
reduction of primary tumor size may allow breast conservation.
In fact, the only demonstrated benefit of preoperative chemo-
therapy in terms of treatment effects is the achievement of tumor
shrinkage sufficient to allow breast saving surgery in some of
the patients (i.e., dependent also on breast size, tumor size, and
conditions allowing radiation therapy to the conserved breast).
Several randomized trials comparing primary chemotherapy
with traditional adjuvant treatment have been published, and no
clear advantage in disease-free survival or overall survival was
observed (5–12). Despite these unsatisfactory results, not a
single trial led to an observation of a trend indicating that
primary chemotherapy was detrimental. Surgical complications
were not more prevalent, and the positive aspect was that more
patients could be offered breast-conserving surgery after pri-
mary systemic treatment.
Preoperative chemotherapy might be advantageous for pa-
tients with breast cancer in several ways in addition to allowing
breast conservation surgery in some of the patients. The re-
sponse to the primary treatment may be used as a prognostic
marker, because it was demonstrated to be associated with a
longer disease-free survival compared with no response (9). Not
only the response but also the type and degree of response
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(pathological complete remission) predict overall outcome in
terms of disease-free survival (9). Finally, observed patterns of
change for various biological features after exposure to primary
treatment might also serve as a surrogate for qualitative and
quantitative prediction of response.
Several strategies can be considered to improve results of
preoperative chemotherapy. On one hand, the introduction of
new drugs in preoperative chemotherapy regimens might pro-
vide some benefit as indicated recently in randomized trials (13,
14). A second useful strategy to improve knowledge about
treatment effects is the early identification of features, which are
associated with response or resistance to primary therapy. Iden-
tifying these features is a crucial step in the development of the
most effective multimodal approaches, using a sequence of local
and systemic treatments and identifying cohorts of patients most
likely to benefit from preoperative chemotherapy.
To seek information on the predictive value of biological
and clinical features we evaluated the course of disease in 399
patients with large operable primary breast cancer who had
preoperative diagnosis and surgery performed at the European
Institute of Oncology.
PATIENTS AND METHODS
Patients. Prospectively collected data from 399 consec-
utive patients with clinical stage T2-T4d, N0–2 treated with
preoperative chemotherapy from 1994 through 2002 were ana-
lyzed. Eligibility criteria for preoperative chemotherapy in-
cluded no previous chemotherapy/hormonotherapy, perform-
ance status 0–2 (Eastern Cooperative Oncology Group scale),
measurable lesions, age between 18 and 70 years, white blood
cells 4,000/mm3; platelets 100,000/mm3, aspartate amino-
transferase, alanine aminotransferase, lactate dehydrogenase,
-GT2.5 upper limit of normal, and bilirubin3 mg/100 mL.
Patients with cardiac disease (congestive heart failure and
history of myocardial infarction within the previous 3 months),
severe vascular disease, or uncontrolled concomitant infections
were excluded. Patients had baseline liver and renal function
tests, electrolyte studies, and complete blood count done within
2 weeks of inclusion in the study. Also, bilateral mammography
and ultrasound, chest X-ray, abdominal ultrasound, bone scan,
serum CA 15.3 determination, and electrocardiography were
performed within 2 weeks from the treatment start.
Each patient gave a written informed consent.
Treatment. Patients were treated with preoperative
chemotherapy given in 3-week cycles. After each cycle disease
was evaluated by clinical measurement of the two largest diam-
eters. Surgery was planned in patients with clinically progress-
ing disease. After three cycles, patients also had mammography
and ultrasound breast examination to assess response. Patients
with stable disease received surgery, and those with partial
remission or complete remission were candidates to receive
three more cycles of therapy, for a maximum of six cycles. The
following regimens were used during the conduct of the study:
(1) anthracycline containing regimens: ECF: E  Epirubicin 25
mg/m2 i.v., days 1 and 2; C Cisplatinum 60 mg/m2 i.v. day 1;
F  Fluorouracil 200 mg/m2/day as continuous infusion days 1
to 21; AC/EC: A doxorubicin 60 mg/m2 or E epirubicin 90
mg/m2 i.v. day 1, C  cyclophosphamide 600 mg/m2 i.v. day 1;
(2) Taxane containing regimens: AT/ET: A  doxorubicin 60
mg/m2 or E  epirubicin 90 mg/m2 i.v. day 1, T  taxotere 75
mg/m2 i.v. day 1; (3) Navelbine containing regimens: ViFuP:
Vi  Vinorelbine (Navelbine) 20 mg total dose i.v. days 1 and
3; Fu  Fluorouracil 200 mg/m2/day as continuous infusion
days 1 to 21; P  (cis)Platinum 60 mg/m2 i.v. day 1; FLN: F 
Fluorouracil 350 mg/m2 i.v. days 1 to 3; L  Lederfolin 100
mg/m2 i.v. days 1 to 3; N  navelbine 20 to 25 mg/m2 i.v. days
1 and 3. For regimens including continuous infusion FU, the
insertion of a central venous catheter (Dome Port, Bard) was
required, and infusion was provided by a Portable Elastomeric
Infusion System (Baxter). Patients were instructed to change
their own infusion bag every week.
Toxicity and Dose Modifications. Toxicity was evalu-
ated according to National Cancer Institute of Cancer—Clinical
Trials Group criteria by clinical and laboratory evaluations at
day 21 of each cycle. If creatinine/blood urea nitrogen was up to
1.5, the upper normal value cisplatin was omitted. In case of
constipation, mucositis, or diarrhea (grade2), the next cycle of
chemotherapy was postponed by 1 or 2 weeks until recovery and
then administered at 75% of the dose. The treatment was post-
poned by 1 week if the blood count on day 21 showed a
neutrophil count 1,000/mm3 and/or platelet count 100,000
mm3. If on day 28 the neutrophil count was 1,000/mm3 and
platelet count 100,000 mm3, the treatment was readminis-
tered. Otherwise, treatment was postponed by another week. If
after 2 weeks of treatment delay (on day 35) hematologic
recovery (neutrophils 1,000 mm3 and platelets 100,000/
mm3) was not obtained, treatment was discontinued.
Response Criteria. Responses were evaluated according
to both radiologic (breast ultrasound plus mammography) and
clinical evaluation and graded according to standard WHO
criteria. Pathological complete remissions were evaluated ac-
cording to Sataloff et al. criteria (15). A pathological complete
remission was defined as a total or near total disappearance of
the tumor. In particular, absence of invasive cancer or presence
of isolated foci of invasive cancer both qualified for patholog-
ical complete remission. Axillary lymph nodes were also as-
sessed independent of the primary tumor for the degree of
pathological response according to the 5th Tumor-Node-Metas-
tasis Staging System (16)
Pathology and Immunohistochemistry. This is a single
institution study. All of the included patients had pathological
evaluation performed at the European Institute of Oncology.
The original receptor status determinations, performed before
the study conduction, were used. Surgical specimens were ex-
tensively sampled for the evaluation of residual tumor after
primary chemotherapy. In case of lack of macroscopic evidence
of tumor the quadrantectomy specimens were entirely blocked
in paraffin and examined histologically, as were the tumor-
bearing quadrants of the mastectomies. In the latter cases, the
other quadrants were also thoroughly evaluated with the exam-
ination of at least three tissue blocks.
Immunostaining experiments for the localization of estro-
gen and progesterone receptors, Her-2/neu protein, and Ki-67
antigen were performed on consecutive tissue sections of the
tru-cut biopsies obtained before primary treatment and from
the residual tumor after surgery, as reported previously (17).
The following primary antibodies were used: the monoclonal
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antibody to estrogen receptor (Dako, at 1:100 dilution), the
monoclonal antibody to progesterone receptor (Dako, 1:800),
the MIB-1 monoclonal antibody to the Ki-67 antigen (Immuno-
tech, Marseille, France, 1:1200), and the polyclonal antiserum
(Dako, 1:3,200) to the Her-2/neu protein.
The immunostained slides were evaluated independently
by two of the authors. Only nuclear reactivity was taken into
account for estrogen receptor, progesterone receptor, and Ki-67
antigen, whereas only an intense and complete membrane stain-
ing10% of the tumor cells was taken as evidence of Her-2/neu
overexpression (3). The results were recorded as the percent-
age of immunoreactive cells over at least 2,000 neoplastic cells.
The median value of Ki-67 labeling index for the cohort of
patients included in the study was used as a cutoff in distin-
guishing tumors with low (25%) and high (25%) prolifera-
tive fraction. Steroid hormone receptors status was classified as
absent (estrogen receptor and progesterone receptor 0% of the
cells positive), low (estrogen receptor and/or progesterone re-
ceptor 1% 10% of the cells), or positive (estrogen receptor
and progesterone receptor 10% of the cells).
Statistical Methods. The primary endpoints were achiev-
ing a pathological complete remission and node-negative status
at final surgery. In addition, we evaluated the impact of estrogen
receptor and progesterone receptor status and of the degree of
response (pathological complete remission and node-negative
status) on disease-free survival. We used logistic regression to
model the probability of achieving a pathological complete
remission first in univariate analyses and then in multiple re-
gression analyses to identify the baseline factors that predicted
a pathological complete remission. Similar analyses were per-
formed for modeling nodal status to identify factors that predict
node-negative status. Odds ratios, 95% confidence intervals
(CI), and Ps were estimated. The Wald test was used to evaluate
significance of individual coefficients, and the likelihood ratio
test was used to assess a factor with more than two levels (e.g.,
tumor size). Factors included in the multiple regression analyses
were menopausal status, estrogen receptor/progesterone recep-
tor status, pathological grade, Ki-67, Her-2/neu, and treatment
regimen. In addition, we explored all of the logistic regression
models that included two baseline factors and the two-way
interaction between those factors. Associations between cate-
gorical variables were assessed by a Fisher’s exact test. Disease-
free survival was calculated from the date of first treatment until
breast cancer recurrence or a new breast cancer primary or death
without recurrence, whichever occurred first. Results are avail-
able at a median follow-up of 3.8 years. Assessment of disease-
free survival according to estrogen receptor/progesterone recep-
tor status, pathological complete remission status, and nodal
status were summarized using the 4-year disease-free survival
percentage and the hazard ratio with the respective 95% CI. Cox
multiple regression analysis was performed to assess factors
predicting disease-free survival. P 0.05 were considered to be
statistically significant. No adjustment was made for performing
multiple tests, and all of the probability values were two sided.
RESULTS
Of the 399 patients with response data, 15.7% had a path-
ological complete remission, 51.3% had objective clinical re-
mission (complete remission  partial remission), 31.3% had
stable disease, and 1.5% had progressive disease. As a result of
the univariate analysis (Table 1), the factors that were signifi-
cantly associated with pathological complete remission were
estrogen receptor/progesterone receptor status (P  0.0001),
grade (P  0.0001), Ki-67 (P  0.0001), and infusional regi-
mens (P  0.01). Within the estrogen receptor/progesterone
receptor absent cohort, 33.3% achieved a pathological complete
remission compared with 7.4% and 7.6% within the estrogen
receptor/progesterone receptor low and positive cohorts, respec-
tively. The pathological complete remission percentage for pa-
tients with grade 3 tumors was 25.7% compared with 7.6% with
grades 1 and 2. For patients with Ki-67 25%, 22.3% achieved
a pathological complete remission compared with 8.1% with
Ki-67  25%. For patients that received infusional therapy,
19.5% had a pathological complete remission versus 10.1% for
patients that received no infusional therapy. Differences in path-
ological complete remission rate according to whether or not an
anthracycline was used were not statistically significant.
For the multivariate analysis, using logistic regression to
model the probability of achieving a pathological complete
remission, we combined the estrogen receptor/progesterone
receptor-positive and estrogen receptor/progesterone receptor-
low cohorts into one group. None of the two-way interactions
were statistically significant.
Using a stepwise selection routine at the 0.05 significance
level on all factors from the univariate analysis, estrogen recep-
tor/progesterone receptor (P  0.0001) and grade (P  0.001)
were the two factors that remained statistically significant in the
model to predict pathological complete remission. Patients
within the estrogen receptor/progesterone receptor absent cohort
were 4.22 times (95% CI, 2.20–8.09, P  0.0001) more likely
to achieve a pathological complete remission than patients
within the estrogen receptor/progesterone receptor-positive or-
low cohort, and patients with grade 3 tumors were 3.36 times
(95% CI, 1.62–7.01, P  0.001) more likely to achieve a
pathological complete remission compared with patients with
grade 1 or 2 tumors.
A total of 388 (97%) patients had pathological examination
of axillary lymph nodes. Of these 388 patients, 28.6% had
node-negative disease at the time of final surgery. As shown in
Table 2 a significant correlation between node-negative status
and pathological complete remission was detected (P 
0.0001). As indicated in Table 1, the factors that were signifi-
cantly associated with nodal status were estrogen receptor/
progesterone receptor status (P  0.0001), clinical tumor size
(P  0.001), and use of infusional regimens (P  0.003).
Using logistic regression to model the probability of being
node-negative at final surgery, none of the two-way interaction
terms were statistically significant. The three factors that
showed a significant association with nodal status in the univa-
riate analysis were also the only three factors that were statis-
tically significant in the multivariate analysis. Patients within
the estrogen receptor/progesterone receptor-absent cohort were
3.47 times (95% CI, 2.09–5.76, P 0.0001) more likely to have
node-negative disease at final surgery than patients within the
estrogen receptor/progesterone receptor-positive or -low cohort,
and patients with T2 tumors were 4.0 times (95% CI, 2.02–7.87,
P  0001) more likely to have node-negative disease than
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patients with T4 tumors, and patients who received infusional
therapy were 2.14 times (95% CI, 1.29–3.57, P  0.003) more
likely to have node-negative disease than patient treated with no
infusional therapy.
We also evaluated the correlation between Her-2/neu over-
expression and response to anthracycline-containing chemother-
apy. A slight increased pathological complete remission rate
was observed for tumors overexpressing Her-2/neu (33 patients)
versus those not overexpressing Her-2/neu (115 patients), al-
though this was not statistically significant (27.3% versus
16.5%, P  0.21). In regimens not containing anthracyclines,
the pathological complete remission rate was similar for Her-2/
neu overexpressing tumors (18 patients) and for tumors not
overexpressing Her-2/neu (39 patients, 11.1% versus 10.3%,
P  0.99). The interaction between Her-2/neu and chemother-
apy regimen was not statistically significant (P 0.82). Eighty-
seven percent of the 336 patients who did not have a patholog-
ical complete remission were assessable for estrogen receptor
and progesterone receptor at both baseline and final surgery.
The changes in estrogen receptor and progesterone receptor
category are shown in Table 3. Estrogen receptor status changed
for 9% of the patients (both pre- and post-menopausal), whereas
progesterone receptor status changed for 26% of premenopausal
patients and 30% of postmenopausal patients. In the present
study no significant correlation between modification in the
expression of biological features and clinical response was
detected, in particular for Ki-67 expression (data not shown).
Despite the significantly higher incidence of pathological
complete remission and node-negative status achieved by pre-
operative chemotherapy for patients with estrogen receptor and
progesterone receptor-absent disease, the disease-free survival
was significantly worse for this cohort compared with the low/
positive expression cohort (4-year disease-free survival: 41%
versus 74%, hazard ratio, 3.22; 95% CI, 2.28–4.54; P 
0.0001; Fig. 1.). Patients who achieve pathological complete
remission had a nonstatistically significant worse disease-free
Table 2 Correlation between pathological complete remission and
nodal status
PCR cCR/cPR
Stable
disease P
% (N) % (N) % (N)
Node-negative 58 (35) 28 (56) 16 (19)
Node-positive 42 (25) 72 (145) 84 (103) 0.0001
Total 100 (60) 100 (201) 100 (122)
Abbreviations: cCR, complete remission; cPR, partial remission.
Table 1 Pathological complete remissions and nodal status at definitive surgery according to baseline factors
Baseline factor
Response Nodal status
Total Pathological CR % (N) P Total Node-negative % (N) P
Total 399 15.7 (63) 388* 28.6 (111)
ER/PgR
Absent 129 33.3 (43) 0.0001 126 42.9 (54) 0.0001
Low† 94 7.4 (7) 91 28.6 (26)
Positive 171 7.6 (13) 167 18.0 (30)
Unknown 5 0.0 (0) 4 25.0 (1)
Menopausal status
Premenopausal 210 14.7 (31) 0.58 206 25.7 (53) 0.22
Postmenopausal 189 16.9 (32) 182 31.9 (58)
Clinical tumor size
T2 235 14.8 (35) 0.81 227 35.7 (81) 0.001
T3 74 17.5 (13) 74 21.6 (16)
T4 90 16.6 (15) 87 16.1 (14)
Grade
Grades 1,2 143 7.6 (11) 0.0001 141 30.5 (43) 0.99
Grade 3 159 25.7 (41) 157 30.6 (48)
Unknown 97 11.3 (11) 90 22.2 (20)
Ki-67
25% 172 8.1 (14) 0.0001 164 25.6 (42) 0.35
25% 210 22.3 (47) 208 30.3 (63)
Unknown 17 11.7 (2) 16 37.5 (6)
Her-2/neu
Intense and complete 51 21.5 (11) 0.28 50 38.0 (19) 0.39
Other 154 14.9 (23) 148 31.1 (46)
Unknown 194 14.9 (29) 190 24.2 (46)
Infusional
Infusional therapy 241 19.5 (47) 0.01 234 34.2 (80) 0.003
No infusional therapy 158 10.1 (16) 154 20.1 (31)
Regimen
Antracyclines 212 15.5 (33) 0.87 203 29.6 (60) 0.46
Antracyclines and taxanes 15 20.0 (3) 15 13.3 (2)
Others 172 15.6 (27) 170 28.8 (49)
* 11 cases did not have axillary lymph nodes examined.
† Defined as estrogen receptor and/or progesterone receptor 1% 10% of the cells.
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survival (57%) than patients who did not achieve pathological
complete remission (64%; hazard ratio, 1.29; 95% CI, 0.83–
2.00; P  0.26), possibly due to the higher proportion of
receptor absent disease in the pathological complete remission
group. Patients who achieve node-negative disease at final sur-
gery had significantly better disease-free survival than patients
with node-positive disease (4-year disease-free survival %: 77%
versus 60%; hazard ratio, 0.51; 95% CI, 0.31–0.82; P 0.005).
In the Cox multiple regression analyses, the receptor status of
the primary tumor was the most significant predictor of disease-
free survival.
DISCUSSION
The most relevant factors for the estimation of risk of
recurrence in patients with early breast cancer after radical
surgery are nodal status, number of nodes involved, presence of
vessel invasion, tumor size, grade, and age (18, 19). Determi-
nation of steroid hormone receptor expression in the primary
tumor is a factor that is mainly used to predict endocrine
responsiveness. Specifically for patients with node-negative dis-
ease, pathological tumor size, grade, and age are factors con-
sidered important for such risk assessment, thus influencing
choice among different treatment options, together with the
status of endocrine responsiveness. Regrettably, the success of
adjuvant treatment can only be postulated when patients remain
free of disease after several years. Conversely to the method
used to choose an adjuvant systemic therapy regimen, the se-
lection of preoperative therapy does not commonly take into
account biological characteristics of the tumor. In fact, very few
features were tested as predictors of preoperative treatment
response indicators, including diameter of the tumor (20) and in
very few patients MIB-1 increased expression (17, 21) or pro-
liferative index (22, 23). A large experience on factors predict-
ing response in the preoperative setting was published recently
and is based on a retrospective analysis of the National Surgical
Adjuvant breast and Bowel Project B-18 study (24). The eval-
uation was performed on 493 patients [fine needle aspiration
cytology of 450 patients and/or sections of core biopsy (Tru-cut)
in only 61 cases]. In this trial in which steroid hormone recep-
tors were not determined in either patients with fine needle
aspiration cytology or those with Tru-cut, the poor nuclear grade
significantly predicted a pathological complete remission. Sim-
ilar results were obtained by using nuclear and histologic grade
on core biopsy material in our series.
Change in the expression of biological features after expo-
sure to the systemic treatment and their possible correlation with
clinical response was studied in small cohorts of patients receiv-
ing primary chemotherapy. Published trials on patients treated
with preoperative chemotherapy or chemoendocrine therapies
showed a positive association between Ki-67 reduction with
treatment and response (25–27). In the present study no signif-
icant correlation between modifications of the expression of
biological features and clinical response was detected. A slight
change in steroid hormone expression, in particular progester-
one receptor expression, was observed. A possible explanation
for the changes in estrogen receptor/progesterone receptor ex-
Fig. 1 Kaplan-Meier plot of DFS according to ER/PgR status of the
primary tumor. Results are reported at 3.8 years of median follow-up.
DFS, disease-free survival; HR, hazards ratio; ER, estrogen receptor;
PgR, progesterone receptor.
Table 3 Changes in ER and PgR expression during chemotherapy (from baseline to final surgery) according to menopausal status
ER premenopausal PgR premenopausal ER postmenopausal PgR postmenopausal
(%) N (%) N (%) N (%) N
Total assessable* c 100 (166) 100 (166) 100 (128) 100 (127)
Unchanged 91 (151) 73 (122) 91 (117) 70 (89)
Changed 9 (15) 26 (44) 9 (11) 30 (38)
Types of change
Pos 3 Low 1 (2) 4 (6) 1 (1) 6 (8)
Pos 3 Absent 3 (5) 13 (22) 3 (4) 9 (11)
Low 3 Pos 1 (2) 2 (4) 0 (0) 2 (3)
Low 3 Absent 1 (2) 1 (2) 1 (1) 1 (1)
Absent 3 Pos 2 (4) 5 (8) 4 (5) 6 (8)
Absent 3 Low 0 (0) 1 (2) 0 (0) 6 (7)
Abbreviations: ER, estrogen receptor; PgR, progesterone receptor, pCR, pathological complete remission.
* Patients with pCR who have ER and PgR values available at both baseline and final surgery.
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pression might be related to tissue sampling issues as indicated
in a small study from Lee et al. (28). It is noteworthy, however,
that premenopausal-aged women were likely to achieve an
endocrine effect with chemotherapy through ovarian function
suppression (29). Also, postmenopausal-aged women may ob-
tain some additional endocrine effect from suppression of adre-
nals (30) due to cytotoxics and steroids. These endocrine actions
of chemotherapy might be the reason for the observed changes
in the expression of steroid hormone receptors.
The relationship between steroid hormone receptor expres-
sion and response to chemotherapy has received little attention
in the past. Two decades have passed since this relationship was
debated with the presentation of conflicting reports in the met-
astatic setting (31, 32). Limited data are available on the rela-
tionship between number of cells expressing hormone receptors
and response to chemotherapy in the preoperative setting. This
might be explained by the heterogeneity of examinations, meth-
ods, and especially cut-offs used in the various studies. The
results of initial immunohistochemical assessment of p53, Her-
2/neu, glutathione S-transferase, Ki-67, pS2, and estrogen
receptor/progesterone receptor in baseline core biopsy samples
of 134 patients from the Bordeaux randomized trial showed that
estrogen receptor-negative status (defined at immunohistochem-
ical evaluation as estrogen receptor10% of the cells) and high
Ki-67 were correlated with clinical tumor response (21). Inter-
estingly, when the analysis was conducted with the dextran-
coated charcoal method, less estrogen receptor-positive tumors
were detected compared with immunohistochemistry (46% ver-
sus 67%), and no significant correlation was detected between
response and estrogen receptor status. A more recently pub-
lished trial showed a significantly higher pathological response
rate for estrogen receptor-negative tumors (defined as 10% of
the cells) compared with estrogen receptor-positive tumors (25).
The largest experience on hormone receptor expression predict-
ing response in the preoperative setting was published recently
and is based on an analysis of the National Surgical Adjuvant
breast and Bowel Project B-27 study (13). Overall, estrogen
receptor-negative tumors had higher pathological response rates
than did estrogen receptor-positive tumors (16.7% versus 8.3%,
respectively, P  0.001). A test of estrogen receptor status by
treatment interaction was not significant (P  0.69), indicating
that estrogen receptor status had little effect on the ability of
preoperative docetaxel to improve pathological response. In the
trials described above, analyses were performed based on a
so-called “receptor-negative grouping,” which combines recep-
tor-absent disease with that expressing low receptor levels. In
the present study, which represents the largest available analysis
conducted by the same team of pathologists on pretreatment
biopsies, we demonstrated a different pattern of response to
chemotherapy for endocrine nonresponsive disease (defined as
steroid hormone receptor absent tumor). Some clinical studies
(33) and gene expression profiling (34, 35) already provide
empirical data that receptor-absent breast cancer is a distinct
entity from that with even low levels of receptor expression.
In the present study both the pathological complete remis-
sion rate and the frequency of node-negative status at final
surgery were significantly higher after preoperative chemother-
apy for patients whose tumors did not express estrogen receptor
and progesterone receptor, compared with the receptor-express-
ing cohort. This emphasizes the chemoresponsiveness of tumors
that do not express any estrogen receptor or progesterone re-
ceptor. Despite the high pathological complete remission rate
and node-negative status, the disease-free survival at 3.8 years
of median follow-up was significantly worse for the receptor-
absent compared with the receptor-present groups. The respon-
siveness of tumors expressing some receptors to endocrine
therapies (e.g., ovarian function suppression, tamoxifen, and
aromatase inhibitors) might explain the different outcome ob-
served. In fact, after surgery patients with endocrine unrespon-
sive disease generally did not received additional systemic ther-
apy, whereas those with endocrine-responsive disease received
additional endocrine treatment postoperatively. These findings
provide substantial additional evidence to support the hypothe-
sis that steroid hormone receptor status of the primary tumor
defines distinct biological entities that require a differentiated
approach to treatment and clinical trial investigation. Separate
analyses according to steroid hormone receptor status must be
prospectively planned for future clinical trials and conducted for
current and past studies whether or not these were prospectively
included in the protocol.
The efficacy of systemic therapy for early breast cancer
depends on features of the treatment as well as the tumor and the
patient. The introduction of taxanes provided encouraging re-
sults in recent trials in the preoperative setting. Smith et al. (14)
reported higher pathological complete remission rate on patients
with large or locally advanced breast cancer who, after four
cycles of cyclophosphamide, doxorubicin, vincristine, and pred-
nisolone, received four courses of taxotere versus four addi-
tional courses of cyclophosphamide, doxorubicin, vincristine,
and prednisolone (34% versus 16%, respectively, P  0.04). In
the National Surgical Adjuvant breast and Bowel Project B-27
the addition of 4 cycles of taxotere after 4 cycles of AC signif-
icantly improved pathological complete remission from 13.7%
to 26.1% (13). Whereas no information on response and endo-
crine responsiveness is available for the former trial, in the
National Surgical Adjuvant breast and Bowel Project trial the
results across all of the age groups are not informative concern-
ing chemosensitivity of the use of taxanes for estrogen receptor-
positive disease. Fifty-six percent of the patients were 49
years old, and 30% were in the 50 to 59 age group. It is likely
that more than two thirds of the patients were premenopausal,
and differential endocrine effects of the chemotherapy regimens
contributed to the finding in the estrogen receptor-positive co-
hort. Furthermore, because tamoxifen was given concurrently
with chemotherapy, the tamoxifen duration was either 24 weeks
or 12 weeks according to treatment assignment making com-
parisons for the receptor-positive cohort quite problematic. In
addition, mixing estrogen receptor absent and estrogen receptor-
low tumors together in the category labeled as estrogen recep-
tor-negative attenuates the chemosensitivity that might have
been observed in the truly endocrine unresponsive cohort.
In conclusion, the present study indicates the importance of
preoperative chemotherapy for patients with estrogen receptor-
and progesterone receptor-absent tumors, as well as the poor
outcome in terms of disease-free survival for this patient pop-
ulation. Additional studies using database analyses or prospec-
tive trials are required to confirm the value and limitations of
primary chemotherapy in endocrine nonresponsive tumors. If
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confirmed, future selection of preoperative treatment should be
based on tumor characteristics such as estrogen receptor and
progesterone receptor status, and the current practice of many
laboratories to report receptor status as merely positive or neg-
ative should change to a more quantitative reporting of routine
receptor determinations to identify the estrogen receptor and
progesterone receptor-absent cohort.
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